TITLE

Long-acting β 2-agonists in asthma: safety concerns

AUTHOR(S)
Wooltorton, Eric
PUB. DATE
October 2005
SOURCE
CMAJ: Canadian Medical Association Journal;10/25/2005, Vol. 173 Issue 9, p1030
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the safety concerns on long-acting Î’2-agonist (LABA) in asthma. Primary and selected secondary outcomes of the Salmeterol Multi-Center Asthma Research Trial; Indications of the LABA.
ACCESSION #
18599390

 

Related Articles

  • Risks of long-acting beta-agonists in achieving asthma control. Bicescu, Gabriela // Maedica - a Journal of Clinical Medicine;2009, Vol. 4 Issue 2, p176 

    The article provides information on the risk of long-acting beta-agonist (LABAs) in the treatment of patients with asthma. It states that asthmatics who used LABAs have improved lung functions and diminished asthma symptoms. It adds that LABAs are well tolerated and have high efficacy in...

  • Anticholinergic drugs for COPD. Elliott, William T. // Infectious Disease Alert;May2011 Pharmacology Watch, p1 

    The article discusses a research study published in the "New England Journal of Medicine" which examined the efficacy of anticholinergic drugs in managing exacerbations among patients with chronic obstructive pulmonary disease. The authors of the report compared the anticholinergic drug...

  • RESPIRATORY DISORDERS.  // Monthly Prescribing Reference;Jan2016, Vol. 32 Issue 1, p240 

    The article offers information on several drugs indicated for the treatment of respiratory disorders such as asthma and chronic obstructive lung disease. The drugs include the Alvesco steroid drug, the Arcapta Neohaler beta-2 agonist and the Asmanex HFA steriod drug from pharmaceutical companies...

  • Effectiveness of Salmeterol in Treating COPD. Miller, Karl // American Family Physician;8/1/1999, Vol. 60 Issue 2, p628 

    Deals with a study that compared the safety and effectiveness of salmeterol with that of ipratropium and placebo in patients with chronic obstructive pulmonary disease. Materials; Methodology; Results; Conclusion; Implications.

  • Adverse effects of Beta2 agonists in asthma treatment.  // American Family Physician;1/1/1994, Vol. 49 Issue 1, p238 

    Focuses on adverse effects of beta2 agonists in the treatment of asthma as reported by Wahneda and colleagues in the September 1993 issue of the `American Review of Respiratory Diseases.' Decrease in forced expiratory volume in one second; Increase in bronchial reactivity.

  • INDACATEROL: A NEW APPROVED MOLECULE TO TREAT COPD. Jaithlia, Rajiv; Dev, Suresh Kr.; Gupta, Akash; Tanwar, Ravindra; Chouhan, Chetan // International Journal of Research in Ayurveda & Pharmacy;Sep2011, Vol. 2 Issue 5, p1518 

    Indacaterol approved as once-daily bronchodilator for chronic obstructive pulmonary disease (COPD). Indacaterol is a new molecular entity in the β2-adrenergic agonist class taken only once a day unlike the currently available β2-adrenergic agonist that helps relax muscles around lung...

  • Management based on partnerships.  // New Zealand Doctor;11/19/2008, p23 

    The article discusses an asthma management plan based on partnerships. The goals of a successful management plan include minimal symptoms, minimal use of rescue medication, and promotion of normal or near-normal lung function. Among the medications that form the backbone of asthma therapy for...

  • Arformoterol: (R,R)-Eformoterol, (R,R)-Formoterol, Arformoterol Tartrate, Eformoterol-Sepracor, Formoterol-Sepracor, R,R-Eformoterol, R,R-Formoterol. Adis International Limited // Drugs in R&D;2004, Vol. 5 Issue 1, p25 

    Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the β[sub 2]-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral centres and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor...

  • Treatment of mild persistent asthma. Kaplan, Alan // Primary Care Respiratory Journal;Dec2008, Vol. 17 Issue 4, p251 

    There are several treatment options available for patients who have mild persistent asthma. After being shown a typical case study and three possible treatment options, three respiratory specialists each selected a different option. The options were: using a combination beclometasone/albuterol...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics